3 ⅐ No. 2 Genetic testing for breast cancer: Where are health care providers in the decision process? Christine M. Velicer, MS1,2, and Stephen Taplin, MD, MPH2,3 Purpose: To identify BRCA1/2 knowledge, genetic testing intentions, and communication patterns in breast cancer survivors (...
Men with aBRCA2mutation also have an increased risk of breast cancer—a 6% lifetime risk compared with the average lifetime risk of 0.1% in US men. Genetic testing Genetic testing can determine whether a person has a specific genetic mutation that can increase the risk of certain diseases or...
BRCA-mutated breast cancer: the unmet need, challenges and therapeutic benefits of genetic testingMutations in the BRCA1 and/or BRCA2 genes (BRCAm) increase the risk of developing breast cancer (BC) and are found in ~5% of unselected patients with the disease. BC resulting from a germline ...
Testing for germlineBRCA1/2 mutations has an established predictive role in breast cancer risk assessment. More recently, studies have also identifiedBRCA1/2 status as clinically relevant in the selection of therapy for patients already diagnosed with breast cancer. Emerging breast and ovarian cancer ...
Who qualifies for BRCA testing? Overall,inheritedbreastcancerdisorders account for a small minority of breast cancers. Genes are the "messages" in each cell of the body that determine the ultimate design of our bodies. Genes can be damaged by the environment. Additionally, people can be born wi...
Patients with a higher likelihood to develop BRCA 1 or BRCA 2 mutations are slipping through the cracks, making testing for these mutations a vital part of any breast cancer treatment plan.
BRCA1BRCA2breast cancer riskcancer predispositionfamilial breast cancergenetic counsellinggenetic testinghereditary breast/ovarian cancermanagementsurveillanceHereditary breast cancer is uncommon, accounting for approximately 5鈥 10% of all breast cancer diagnoses. However, it is critical to identify individuals ...
Currently, early age of onset of cancer and a strong family history are relied upon as the chief clues as to who should be offered genetic testing. Certain morphologic and immunohistochemical features are overrepresented in BRCA1-associated breast cancers but these differences have not been ...
The study was limited in that it did not include patients with a BRCA1/2 variant who were unaware or never underwent testing. There was also bias among survival and cancer event risk estimates when receiving genetic testing. Overall, most patients did not have another cancer event and ...
Development of Breast Cancer Choices: a decision support tool for young women with breast cancer deciding whether to have genetic testing for BRCA1/2 mutations 来自 国家科技图书文献中心 喜欢 0 阅读量: 30 作者: C Grimmett,C Brooks,A Recio-Saucedo,A Armstrong,RI Cutress,DG Evans,E Copson,L ...